Teragen Bio, a company specializing in genome analysis, announced that it has been selected as the final implementation organization for the "Personalized Anticancer Vaccine Development Platform (PAVE)" project, part of the "Korean ARPA-H Project," promoted by the Ministry of Health and Welfare. This project is a state-led R&D project with a research budget of up to 19.1 billion won over approximately four years and six months.
Teragen Bio is participating in the 'NeoVax-K Consortium' with Aston Science (host organization), IMBDX, GeneEdit, and Korea University Anam Hospital, and plans to jointly develop a patient-tailored anticancer vaccine based on mRNA vaccine technology.
In this project, Teragen Bio will analyze the genomic data of pancreatic cancer patients and predict and validate neoantigen candidates based on its proprietary technologies, including DeepOmicsFFPETM, DeepOmicsNeoTM, and Double Barcode Neoepitope ScanTM. Through this, the company aims to improve prediction accuracy, which was previously low compared to existing methods, to over 90%.
Additionally, we plan to simultaneously design and develop optimized mRNA structures and processes for anticancer vaccine production, and establish small-scale mRNA GMP production facilities in Korea to establish an industrial infrastructure for vaccine and therapeutic development.
Teragen Bio CEO Baek Sun-myung praised this project selection as a result of the research capabilities accumulated over the past several years. He stated that he will collaborate with consortium participating institutions to develop practical treatments for intractable cancers with limited treatment options, such as pancreatic cancer, certain subtypes of colon cancer, and pediatric and adolescent cancers. He also expressed his commitment to contributing to the creation of an mRNA-based industrial ecosystem.
- See more related articles
You must be logged in to post a comment.